IN THE CLAIMS

1. (currently amended) A pharmaceutical tablet comprising <u>stabilized</u> fosinopril sodium and <u>the lubricant</u> zinc stearate <u>wherein the presence of the lubricant results in a significant reduction in products of degradation for the tablet in comparison to other known lubricants such as magnesium stearate, and calcium stearate.</u>

claims 2 to 5 (cancelled)

- 6. (currently amended) A The tablet as in of claim 1 further comprising lactose.
- 7. (currently amended) A tablet as in claim 1 or 6 wherein the amount of lubricant by weight is from about about 0.3 percent to about 4.0 percent of the total tablet weight.

Claims 8 to 10 (cancelled)